Zalicus To Present at the Rodman & Renshaw Annual Global Investment Conference NYC

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Press Kit Materials are Available at: http://www.tradeshownews.com/events/Rodman-Renshaw-Annual-Global-Investment-Conference-NYC/zalicus/.

Company:		Zalicus Inc.
		Rodman & Renshaw Annual Global Investment Conference NYC
Event:		Sep 13 - 15, 2010
		New York, NY, US
Web:		http://www.zalicus.com

About Zalicus Inc.

Zalicus Inc. (NASDAQ: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators. To learn more about Zalicus, please visit www.zalicus.com.

Contacts

Zalicus Inc.
Company Contact
Justin Renz, 617-301-7575
jrenz@zalicus.com
or
IR Contact
Gina Nugent, 857-753-6562
gnugent@zalicus.com

Recent Stories from Zalicus Inc.

Zalicus to Present at Two Upcoming Investor Conferences

May 09, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory dise... more »
Zalicus Reports Financial Results for the First Quarter 2012

May 03, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the first quarter ended March 31, 2012. “We made tremendous progress advancing our pipeline this ... more »
Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, into Multiple Phase 2a Clinical Trials for the Treatment of Pain

May 02, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus advancing Z160, in multiple chronic pain clinical trials. Formulation selected - will initiate two Phase 2a clinical trials; the first to begin enrolling ... more »